Clinical Trials Logo

Clinical Trial Summary

This study proposes to examine the relationship between the development of impaired glucose tolerance, the phenotype of CFLD, and risk of liver fibrosis.


Clinical Trial Description

Pancreas insufficiency is a well-established risk factor for development of CF related diabetes (CFRD), but increased insulin resistance has also been demonstrated in this population. Cystic fibrosis liver disease (CFLD) is a well-established risk factor for the development CFRD. In addition, patients with CFLD and CFRD at high risk of development of severe CFLD and cirrhosis. Recent work has shown that male CF patients with abnormal oral glucose tolerance tests were noted to have elevations in ALT but the significance of this finding has yet to be fully explored. Specifically, an unresolved question remains on whether the elevation in ALT reflects a steatohepatitis as would be observed in a non-CF population or if the increased insulin resistance contributes to fibrosis progression in the classic biliary type cirrhosis seen in cystic fibrosis (CF). Metabolic dysfunction with increasing insulin resistance has been shown to be a key component to the development of non-alcoholic steatosis hepatitis in a non-CF population. The presence of hepatic steatosis has been demonstrated in the CF population, but thus far not been linked to the development of significant steatohepatitis or cirrhosis. One potential explanation for this discordance between effects of hepatic steatosis in the CF and non-CF population, is in the non-CF population it requires multiple decades for hepatic steatosis to result in steatohepatitis and progression to cirrhosis, therefore the progressive fibrosis may not be seen in the CF population due to limited life expectancy. However, as the life expectancy in of patients with CF is increasing with new therapy, the longer-term consequences of hepatic steatosis maybe apparent Alternatively, the presence of increased insulin resistance has been correlated to increase fibrosis progression in other forms of liver disease such as hepatitis C. Therefore, another potential mechanism is the insulin resistance seen in patients with CFRD results in increased fibrosis and development of cirrhosis in patients with classic CFLD. Thus, further characterizing the underlying liver disease phenotype and fibrosis risk in this population is of interest. We propose to examine the relationship between the development of impaired glucose tolerance, the phenotype of CFLD, and risk of liver fibrosis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05229640
Study type Interventional
Source Dartmouth-Hitchcock Medical Center
Contact
Status Withdrawn
Phase N/A
Start date March 31, 2022
Completion date December 2023

See also
  Status Clinical Trial Phase
Completed NCT02723968 - Cystic Fibrosis Related Diabetes Screening. N/A
Completed NCT04503408 - A Comparison of Clinical Parameters in With and Without Abnormal Glucose Tolerance.
Recruiting NCT05723445 - The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes N/A
Completed NCT04519853 - A Pilot Study of a Low Glycemic Load Diet in Adults With Cystic Fibrosis N/A
Terminated NCT03234387 - A CFit Study - Baseline
Completed NCT03227094 - Simplification of CF-related Diabetes Screening at Home N/A
Completed NCT03961516 - Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis
Terminated NCT03237767 - A CFit Study - Acute Exercise N/A
Active, not recruiting NCT04533646 - Comparison of Meal-Time Dosing of Insulin in Cystic Fibrosis Related Diabetes Phase 4
Recruiting NCT05766774 - FEED-Cystic Fibrosis (FEED-CF) N/A
Not yet recruiting NCT06449677 - Bionic Pancreas in CFRD Phase 3
Terminated NCT03939065 - Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management N/A
Completed NCT02810691 - The Effect of Soluble Fiber to Reduce Post-prandial Glycemic Excursion in Adults With Cystic Fibrosis N/A
Recruiting NCT05568134 - Alternate Measures of Glucose During OGTT Testing for CFRD
Recruiting NCT05463289 - ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2 N/A
Not yet recruiting NCT04379726 - β-cell Function and Insulin Sensitivity in Patients With Cystic Fibrosis
Completed NCT03650712 - EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis N/A
Active, not recruiting NCT06084468 - Cardiac Structure and Function in Patients With Cystic Fibrosis
Recruiting NCT04530383 - Effects of Metformin on Airway Ion Channel Dysfunction in Cystic Fibrosis-related Diabetes Phase 2
Recruiting NCT06149793 - SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes Phase 2/Phase 3